149 related articles for article (PubMed ID: 35156181)
21. Valuation of Health States Considered to Be Worse Than Death-An Analysis of Composite Time Trade-Off Data From 5 EQ-5D-5L Valuation Studies.
Gandhi M; Rand K; Luo N
Value Health; 2019 Mar; 22(3):370-376. PubMed ID: 30832976
[TBL] [Abstract][Full Text] [Related]
22. Time trade-off with someone to live for: impact of having significant others on time trade-off valuations of hypothetical health states.
Hansen TM; Stavem K; Rand K
Qual Life Res; 2022 Apr; 31(4):1199-1207. PubMed ID: 34718936
[TBL] [Abstract][Full Text] [Related]
23. Elicitation of Norwegian EQ-5D-5L values for hypothetical and experience-based health states based on the EuroQol Valuation Technology (EQ-VT) protocol.
Hansen TM; Helland Y; Augestad LA; Rand K; Stavem K; Garratt A
BMJ Open; 2020 Jun; 10(6):e034683. PubMed ID: 32532768
[TBL] [Abstract][Full Text] [Related]
24. A Time Trade-off-derived Value Set of the EQ-5D-5L for Canada.
Xie F; Pullenayegum E; Gaebel K; Bansback N; Bryan S; Ohinmaa A; Poissant L; Johnson JA;
Med Care; 2016 Jan; 54(1):98-105. PubMed ID: 26492214
[TBL] [Abstract][Full Text] [Related]
25. A program of methodological research to arrive at the new international EQ-5D-5L valuation protocol.
Oppe M; Devlin NJ; van Hout B; Krabbe PF; de Charro F
Value Health; 2014 Jun; 17(4):445-53. PubMed ID: 24969006
[TBL] [Abstract][Full Text] [Related]
26. Valuing Health Using Time Trade-Off and Discrete Choice Experiment Methods: Does Dimension Order Impact on Health State Values?
Mulhern B; Shah K; Janssen MF; Longworth L; Ibbotson R
Value Health; 2016; 19(2):210-7. PubMed ID: 27021755
[TBL] [Abstract][Full Text] [Related]
27. Valuing Health State: An EQ-5D-5L Value Set for Ethiopians.
Welie AG; Gebretekle GB; Stolk E; Mukuria C; Krahn MD; Enquoselassie F; Fenta TG
Value Health Reg Issues; 2020 Sep; 22():7-14. PubMed ID: 31683254
[TBL] [Abstract][Full Text] [Related]
28. Reporting and valuing one's own health: a think aloud study using EQ-5D-5L, EQ VAS and a time trade-off question among patients with a chronic condition.
Ernstsson O; Burström K; Heintz E; Mølsted Alvesson H
Health Qual Life Outcomes; 2020 Dec; 18(1):388. PubMed ID: 33334348
[TBL] [Abstract][Full Text] [Related]
29. 3125 steps to perfect health: a nonparametric approach to developing the EQ-5D-5L value set.
Thomas S; Johnson JA; Xie F
Qual Life Res; 2020 Nov; 29(11):3109-3118. PubMed ID: 32705459
[TBL] [Abstract][Full Text] [Related]
30. Overview, Update, and Lessons Learned From the International EQ-5D-5L Valuation Work: Version 2 of the EQ-5D-5L Valuation Protocol.
Stolk E; Ludwig K; Rand K; van Hout B; Ramos-Goñi JM
Value Health; 2019 Jan; 22(1):23-30. PubMed ID: 30661630
[TBL] [Abstract][Full Text] [Related]
31. Investigating 5-Level EQ-5D (EQ-5D-5L) Values Based on Preferences of Patients With Heart Disease.
Gandhi M; Tan RS; Lim SL; Rand K; Lam CSP; Luo N; Cheung YB
Value Health; 2022 Mar; 25(3):451-460. PubMed ID: 35227458
[TBL] [Abstract][Full Text] [Related]
32. Learning effects in time trade-off based valuation of EQ-5D health states.
Augestad LA; Rand-Hendriksen K; Kristiansen IS; Stavem K
Value Health; 2012; 15(2):340-5. PubMed ID: 22433766
[TBL] [Abstract][Full Text] [Related]
33. Completing the time trade-off with respondents who are older, in poorer health or with an immigrant background in an EQ-5D-5L valuation study.
Hansen TM; Stavem K; Rand K
Eur J Health Econ; 2023 Aug; 24(6):877-884. PubMed ID: 36053383
[TBL] [Abstract][Full Text] [Related]
34. Estimating the EQ-5D-5L value set for the Philippines.
Miguel RTD; Rivera AS; Cheng KJG; Rand K; Purba FD; Luo N; Zarsuelo MA; Genuino-Marfori AJ; Florentino-Fariñas I; Guerrero AM; Lam HY
Qual Life Res; 2022 Sep; 31(9):2763-2774. PubMed ID: 35532835
[TBL] [Abstract][Full Text] [Related]
35. Parallel Valuation of the EQ-5D-3L and EQ-5D-5L by Time Trade-Off in Hungary.
Rencz F; Brodszky V; Gulácsi L; Golicki D; Ruzsa G; Pickard AS; Law EH; Péntek M
Value Health; 2020 Sep; 23(9):1235-1245. PubMed ID: 32940242
[TBL] [Abstract][Full Text] [Related]
36. The Egyptian EQ-5D-5L Extensive Pilot Study: Lessons Learned.
Al Shabasy S; Roudijk B; Abbassi M; Finch A; Stolk E; Farid S
Pharmacoeconomics; 2023 Mar; 41(3):329-338. PubMed ID: 36434416
[TBL] [Abstract][Full Text] [Related]
37. Health-related quality of life measured with the EQ-5D-5L: estimation of normative index values based on a representative German population sample and value set.
Grochtdreis T; Dams J; König HH; Konnopka A
Eur J Health Econ; 2019 Aug; 20(6):933-944. PubMed ID: 31030292
[TBL] [Abstract][Full Text] [Related]
38. Handling Data Quality Issues to Estimate the Spanish EQ-5D-5L Value Set Using a Hybrid Interval Regression Approach.
Ramos-Goñi JM; Craig BM; Oppe M; Ramallo-Fariña Y; Pinto-Prades JL; Luo N; Rivero-Arias O
Value Health; 2018 May; 21(5):596-604. PubMed ID: 29753358
[TBL] [Abstract][Full Text] [Related]
39. Exploring the importance of controlling heteroskedasticity and heterogeneity in health valuation: a case study on Dutch EQ-5D-5L.
Karim S; Craig BM; Groothuis-Oudshoorn CGM
Health Qual Life Outcomes; 2022 May; 20(1):85. PubMed ID: 35614472
[TBL] [Abstract][Full Text] [Related]
40. Use of a Non-parametric Bayesian Method to Model Health State Preferences: An Application to Polish and Irish EQ-5D-5L Valuations.
Kharroubi SA; Kelleher D
Front Public Health; 2022; 10():917728. PubMed ID: 35812518
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
